Arhalofenate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H319820

CAS#: 24136-23-0

Description: Arhalofenate, also known as JNJ-39659100 and MBX102, ) is a selective, partial PPAR-γ agonist that lowers glucose in the absence of some of the side effects, such as weight gain and edema, that are observed with the TZDs. Arhalofenate also displays pronounced triglyceride lowering in preclinical rodent models and in humans.

Chemical Structure

img
Arhalofenate
CAS# 24136-23-0
Instruction

Theoretical Analysis

Hodoodo Cat#: H319820
Name: Arhalofenate
CAS#: 24136-23-0
Chemical Formula: C19H17ClF3NO4
Exact Mass: 415.08
Molecular Weight: 415.793
Elemental Analysis: C, 54.89; H, 4.12; Cl, 8.53; F, 13.71; N, 3.37; O, 15.39

Price and Availability

Size Price Availability Quantity
5mg USD 250 2 Weeks
25mg USD 900 2 Weeks
Bulk inquiry

Synonym: JNJ-39659100; JNJ39659100; JNJ 39659100; MBX102; MBX-102; MBX 102; Arhalofenate

IUPAC/Chemical Name: 2-acetamidoethyl (R)-2-(4-chlorophenyl)-2-(3-(trifluoromethyl)phenoxy)acetate

InChi Key: BJBCSGQLZQGGIQ-QGZVFWFLSA-N

InChi Code: InChI=1S/C19H17ClF3NO4/c1-12(25)24-9-10-27-18(26)17(13-5-7-15(20)8-6-13)28-16-4-2-3-14(11-16)19(21,22)23/h2-8,11,17H,9-10H2,1H3,(H,24,25)/t17-/m1/s1

SMILES Code: O=C(OCCNC(C)=O)[C@@H](C1=CC=C(Cl)C=C1)OC2=CC=CC(C(F)(F)F)=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 415.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Fields TR. The Challenges of Approaching and Managing Gout. Rheum Dis Clin North Am. 2019 Feb;45(1):145-157. doi: 10.1016/j.rdc.2018.09.009. PMID: 30447743.


2: McWherter C, Choi YJ, Serrano RL, Mahata SK, Terkeltaub R, Liu-Bryan R. Arhalofenate acid inhibits monosodium urate crystal-induced inflammatory responses through activation of AMP-activated protein kinase (AMPK) signaling. Arthritis Res Ther. 2018 Sep 6;20(1):204. doi: 10.1186/s13075-018-1699-4. PMID: 30189890; PMCID: PMC6127987.


3: Wang G, Zuo T, Li R. The mechanism of Arhalofenate in alleviating hyperuricemia-Activating PPARγ thereby reducing caspase-1 activity. Drug Dev Res. 2020 Nov;81(7):859-866. doi: 10.1002/ddr.21699. Epub 2020 Jun 7. PMID: 32506648.


4: Abhishek A. New urate-lowing therapies. Curr Opin Rheumatol. 2018 Mar;30(2):177-182. doi: 10.1097/BOR.0000000000000476. PMID: 29251661.


5: Neogi T, Choi HK. Editorial: Pursuit of a Dual-Benefit Antigout Drug: A First Look at Arhalofenate. Arthritis Rheumatol. 2016 Aug;68(8):1793-6. doi: 10.1002/art.39687. PMID: 26990165; PMCID: PMC4982369.


6: Blake KEG, Saag JL, Saag KG. What's new on the front-line of gout pharmacotherapy? Expert Opin Pharmacother. 2022 Mar;23(4):453-464. doi: 10.1080/14656566.2021.2020249. Epub 2022 Jan 5. PMID: 34935576.


7: Cicero AFG, Fogacci F, Kuwabara M, Borghi C. Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update. Medicina (Kaunas). 2021 Jan 10;57(1):58. doi: 10.3390/medicina57010058. PMID: 33435164; PMCID: PMC7827966.


8: Bardin T, Richette P. Novel uricosurics. Rheumatology (Oxford). 2018 Jan 1;57(suppl_1):i42-i46. doi: 10.1093/rheumatology/kex433. PMID: 29272511.


9: Barranco C. Crystal arthritis: Arhalofenate safely prevents gout flare. Nat Rev Rheumatol. 2016 May;12(5):252. doi: 10.1038/nrrheum.2016.53. Epub 2016 Apr 7. PMID: 27052485.


10: Poiley J, Steinberg AS, Choi YJ, Davis CS, Martin RL, McWherter CA, Boudes PF; Arhalofenate Flare Study Investigators. A Randomized, Double-Blind, Active- and Placebo-Controlled Efficacy and Safety Study of Arhalofenate for Reducing Flare in Patients With Gout. Arthritis Rheumatol. 2016 Aug;68(8):2027-34. doi: 10.1002/art.39684. PMID: 26989892; PMCID: PMC5129473.


11: Stamp LK, Merriman TR, Singh JA. Expert opinion on emerging urate-lowering therapies. Expert Opin Emerg Drugs. 2018 Sep;23(3):201-209. doi: 10.1080/14728214.2018.1527899. PMID: 30244605.


12: Shahid H, Singh JA. Investigational drugs for hyperuricemia. Expert Opin Investig Drugs. 2015;24(8):1013-30. doi: 10.1517/13543784.2015.1051617. Epub 2015 Jun 14. PMID: 26073200.


13: Pascart T, Richette P. Investigational drugs for hyperuricemia, an update on recent developments. Expert Opin Investig Drugs. 2018 May;27(5):437-444. doi: 10.1080/13543784.2018.1471133. Epub 2018 May 9. PMID: 29718730.


14: Steinberg AS, Vince BD, Choi YJ, Martin RL, McWherter CA, Boudes PF. The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout. J Rheumatol. 2017 Mar;44(3):374-379. doi: 10.3899/jrheum.161062. Epub 2016 Dec 15. PMID: 27980008.


15: Edwards NL, So A. Emerging therapies for gout. Rheum Dis Clin North Am. 2014 May;40(2):375-87. doi: 10.1016/j.rdc.2014.01.013. Epub 2014 Feb 20. PMID: 24703353.


16: Terkeltaub R. Emerging uricosurics for gout. Expert Rev Clin Pharmacol. 2017 Mar;10(3):247-249. doi: 10.1080/17512433.2017.1271709. Epub 2016 Dec 22. PMID: 27937050.


17: Pascart T, Richette P. Current and future therapies for gout. Expert Opin Pharmacother. 2017 Aug;18(12):1201-1211. doi: 10.1080/14656566.2017.1351945. Epub 2017 Jul 28. PMID: 28689430.


18: Sattui SE, Gaffo AL. Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. Ther Adv Musculoskelet Dis. 2016 Aug;8(4):145-59. doi: 10.1177/1759720X16646703. Epub 2016 May 2. PMID: 27493693; PMCID: PMC4959626.


19: Strilchuk L, Fogacci F, Cicero AF. Safety and tolerability of available urate-lowering drugs: a critical review. Expert Opin Drug Saf. 2019 Apr;18(4):261-271. doi: 10.1080/14740338.2019.1594771. Epub 2019 Mar 27. PMID: 30915866.


20: Keenan RT, Schlesinger N. New and Pipeline Drugs for Gout. Curr Rheumatol Rep. 2016 Jun;18(6):32. doi: 10.1007/s11926-016-0579-7. PMID: 27097819.